Predictors of Incident Depression in Systemic Lupus Erythematosus

Huang, Xuanping; Magder, Laurence S.; Petri, Michelle

doi:10.3899/jrheum.140111

Cited by 59 publications

(77 citation statements)

References 42 publications

(75 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other contributing factors were recent SLE diagnosis, non-Asian ethnicity, cutaneous disease, and longitudinal myelitis. These results may further support the notion that, at least for some patients, SLE related depression is associated with adverse events of therapy rather than with disease activity and may encourage clinicians to reduce prednisone doses or avoid its use [59]. An association of depression and specific antibodies directed at ribosomal-P, NMDA receptor, and other neuronal epitopes have been suggested [9,60].…”

Section: Reviewmentioning

confidence: 53%

“…A recent study concluded that depression in SLE is linked to several factors of which the usage of high dose prednisone (20 mg or higher) was found to be the most significant independent factor, while global disease activity was not [59]. Other contributing factors were recent SLE diagnosis, non-Asian ethnicity, cutaneous disease, and longitudinal myelitis.…”

Section: Reviewmentioning

confidence: 99%

See 1 more Smart Citation

Neuropsychiatric lupus: a mosaic of clinical presentations

Kivity

Agmon‐Levin

Zandman‐Goddard

et al. 2015

BMC Med

172

143

View full text Add to dashboard Cite

Neuropsychiatric symptoms affect nearly half of the patients with systemic lupus erythematosus; however, the effect on disease severity, quality of life, and prognosis is tremendous. Symptoms of neuropsychiatric systemic lupus erythematosus may range from mild diffuse ones, to acute life threatening events. Although the underlying mechanisms are still largely unraveled, several pathogenic pathways are identified, such as antibody-mediated neurotoxicity, vasculopathy due to anti-phospholipid antibodies and other mechanisms, and cytokine-induced neurotoxicity. In the current review, we describe the old and the new regarding epidemiology, pathophysiology, diagnosis, and management of neuropsychiatric systemic lupus erythematosus. The possible link between neuropsychiatric symptoms and specific mechanisms may help to facilitate our understanding of the disease in the future, thus allowing for better treatment strategies.

show abstract

Section: Reviewmentioning

confidence: 53%

Section: Reviewmentioning

confidence: 99%

Neuropsychiatric lupus: a mosaic of clinical presentations

Kivity

Agmon‐Levin

Zandman‐Goddard

et al. 2015

BMC Med

172

143

View full text Add to dashboard Cite

show abstract

“…They are often unrelated to periods of disease activity as conventionally defined (4)(5)(6)(7)(15)(16)(17)(18)(19)(20)(21) and usually do not respond to therapy with immunosuppression or corticosteroids, even with escalation of doses. Such symptoms tend to be chronic.…”

Section: Type 2 Manifestationsmentioning

confidence: 99%

A Novel System to Categorize the Symptoms of Systemic Lupus Erythematosus

Pisetsky

Clowse

Criscione-Schreiber

et al. 2019

Arthritis Care & Research

View full text Add to dashboard Cite

“…Further, among individuals with RA, most depressive disorders developed within five years after RA diagnosis [151]. When examining a cohort of 1,609 individuals with no prior history of depression and SLE, it was found that incidence of depression was as high as 29.7 episodes per 1000 person-years [152]. …”

Section: Incident Depression and Arthritismentioning

confidence: 99%

Healthcare burden of depression in adults with arthritis

Sambamoorthi

Shah

Zhao

2017

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

Introduction Arthritis and depression are two of the top disabling conditions. When arthritis and depression exist in the same individual, they can interact with each other negatively and pose a significant healthcare burden on the patients, their families, payers, healthcare systems, and society as a whole. Areas covered The primary objective of this review is to summarize, identify knowledge gaps and discuss the challenges in estimating the healthcare burden of depression among individuals with arthritis. Electronic literature searches were performed on PubMed, Embase, EBSCOhost, Scopus, the Cochrane Library, and Google Scholar to identify relevant studies. Expert Commentary Our review revealed that the prevalence of depression varied depending on the definition of depression, type of arthritis, tools and threshold points used to identify depression, and the country of residence. Depression exacerbated arthritis-related complications as well as pain and was associated with poor health-related quality of life, disability, mortality, and high financial burden. There were significant knowledge gaps in estimates of incident depression rates, depression attributable disability, and healthcare utilization, direct and indirect healthcare costs among individuals with arthritis.

show abstract

Predictors of Incident Depression in Systemic Lupus Erythematosus

Cited by 59 publications

References 42 publications

Neuropsychiatric lupus: a mosaic of clinical presentations

Neuropsychiatric lupus: a mosaic of clinical presentations

A Novel System to Categorize the Symptoms of Systemic Lupus Erythematosus

Healthcare burden of depression in adults with arthritis

Contact Info

Product

Resources

About